- Home
- KURA vs BRSP Comparison
KURA vs BRSP Comparison
Compare KURA & BRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KURA | BRSP |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 841.6M | 738.7M |
| IPO Year | 2015 | 2017 |
Fundamental Metrics
Financial Performance| Metric | KURA | BRSP |
|---|---|---|
| Price | $11.04 | $5.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 3 |
| Target Price | ★ $25.56 | $6.50 |
| AVG Volume (30 Days) | 1.7M | ★ 2.1M |
| Earning Date | 05-12-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 11.03% |
| EPS Growth | N/A | ★ 75.24 |
| EPS | N/A | ★ 0.03 |
| Revenue | $67,482,000.00 | ★ $330,587,000.00 |
| Revenue This Year | $28.28 | N/A |
| Revenue Next Year | $106.37 | $17.54 |
| P/E Ratio | ★ N/A | $181.33 |
| Revenue Growth | ★ 25.24 | N/A |
| 52 Week Low | $5.45 | $4.84 |
| 52 Week High | $12.49 | $6.17 |
Technical Indicators
Market Signals| Indicator | KURA | BRSP |
|---|---|---|
| Relative Strength Index (RSI) | 64.71 | 38.16 |
| Support Level | $8.53 | $5.06 |
| Resistance Level | $11.29 | $5.46 |
| Average True Range (ATR) | 0.49 | 0.14 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 89.29 | 24.14 |
Price Performance
Historical ComparisonAbout KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
About BRSP BrightSpire Capital Inc.
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.